Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 7/20 | 0.38 |
| ▸ | FYN | P06241 | 3/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24460329 | 0.95 | PIK3CA (0.42) | KCNH2CLK1CYP1A2PIK3CAMTOR | |
| SCHEMBL19781539 | 0.86 | CLK1 (0.47) | KCNH2CLK1CYP1A2PIK3CAMTOR | |
| SCHEMBL24460257 | 0.86 | KCNH2 (0.45) | KCNH2CLK1PIK3CAMTORRIPK2 | |
| SCHEMBL24460322 | 0.86 | CLK1 (0.42) | KCNH2CLK1CYP1A2PIK3CAMTOR | |
| SCHEMBL24460271 | 0.86 | CLK1 (0.42) | KCNH2CLK1CYP1A2PIK3CAMTOR | |
| SCHEMBL19781134 | 0.84 | CLK1 (0.43) | KCNH2CLK1CYP1A2PIK3CAMTOR | |
| SCHEMBL19781808 | 0.84 | FYN (0.52) | KCNH2CLK1CYP1A2PIK3CAMTOR | |
| SCHEMBL24460256 | 0.84 | CLK1 (0.40) | KCNH2CLK1CYP1A2PIK3CAMTOR | |
| SCHEMBL24460267 | 0.84 | RIPK2 (0.40) | KCNH2CLK1CYP1A2PIK3CAMTOR | |
| SCHEMBL19781179 | 0.83 | SCN5A (0.46) | KCNH2CLK1CYP1A2PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2022108849-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | C3AR1, C9, C1R | KCNH2 649/4885CLK1 3537/4885CYP1A2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.